Phoenix Wealth Advisors Sells 1,086 Shares of Pfizer Inc. (NYSE:PFE)

Phoenix Wealth Advisors lessened its position in Pfizer Inc. (NYSE:PFE) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,978 shares of the biopharmaceutical company’s stock after selling 1,086 shares during the quarter. Phoenix Wealth Advisors’ holdings in Pfizer were worth $238,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its holdings in shares of Pfizer by 2.8% during the 2nd quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock worth $20,684,000 after purchasing an additional 20,140 shares during the period. ProShare Advisors LLC increased its holdings in shares of Pfizer by 7.3% during the 2nd quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock worth $23,661,000 after purchasing an additional 57,825 shares during the period. Providence Capital Advisors LLC increased its holdings in shares of Pfizer by 1.7% during the 2nd quarter. Providence Capital Advisors LLC now owns 113,143 shares of the biopharmaceutical company’s stock worth $3,166,000 after purchasing an additional 1,855 shares during the period. Cheviot Value Management LLC increased its holdings in shares of Pfizer by 5.5% during the 2nd quarter. Cheviot Value Management LLC now owns 427,539 shares of the biopharmaceutical company’s stock worth $11,963,000 after purchasing an additional 22,112 shares during the period. Finally, Samlyn Capital LLC increased its holdings in shares of Pfizer by 41.8% during the 2nd quarter. Samlyn Capital LLC now owns 4,906,703 shares of the biopharmaceutical company’s stock worth $137,290,000 after purchasing an additional 1,446,582 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.2 %

Shares of NYSE PFE opened at $26.63 on Wednesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a market cap of $150.89 billion, a PE ratio of 35.98, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $26.09 and a two-hundred day moving average of $27.97.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm posted ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.46%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is 227.03%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Finally, UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.